We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03444376
Recruitment Status : Active, not recruiting
First Posted : February 23, 2018
Last Update Posted : April 6, 2022
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
Genexine, Inc.

Brief Summary:
A Multi-Center, Open-label Phase Ib-II Trial of the Combination of GX-188E Vaccination and Pembrolizumab in Patients with Advanced, Non-Resectable HPV-Positive Cervical Cancer

Condition or disease Intervention/treatment Phase
Cervical Cancer Drug: GX-188E Drug: Keytruda Phase 1 Phase 2

Detailed Description:
This is an open-label Phase Ib-II trial to evaluate the safety and efficacy of GX-188E (IM administration using Ichor TDS-IM device) + pembrolizumab (P) in patients with advanced HPV-16+ or HPV-18+ cervical cancer.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-Center, Open-label Phase Ib-II Trial of the Combination of GX-188E Vaccination and Pembrolizumab in Patients With Advanced, Non-Resectable HPV Type 16 and/or 18 Positive Cervical Cancer
Actual Study Start Date : May 23, 2018
Estimated Primary Completion Date : December 31, 2022
Estimated Study Completion Date : December 31, 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: GX-188E, Keytruda
GX-188E: 1st day of week 1,2,4,7,13,19, 46/ 2mg Keytruda:Day 1 q3 weeks/ 200mg
Drug: GX-188E
GX-188E (1.0mg/0.5ml/vial), Intramuscular administration using electroporator, Ichor TDS-IM device
Other Name: Ichor Tri-Grid Delivery System

Drug: Keytruda
pembrolizumab(100mg/4mL/vial), Intravenous administration
Other Name: Pembrolizumab

Primary Outcome Measures :
  1. DLT evaluation for safety and tolerability(part A) [ Time Frame: within 21days ]
    Patient will be evaluated for the first 21 days for dose-limiting toxicities.

  2. ORR for efficacy(part B&C) [ Time Frame: within 24 weeks ]
    ORR within 24 weeks (ORR24) evaluated by RECIST v1.1

Secondary Outcome Measures :
  1. ORR for efficacy(part A) [ Time Frame: up to 1 year ]
    Overall Response Rate within 24 weeks (ORR24) by RECIST v1.1 and immune-related Response Criteria (irRC)

  2. BORR (part B&C) [ Time Frame: up to 1 year ]
    Best Overall Response Rate(BORR24) by RECIST v1.1

  3. Time-to-Best Response [ Time Frame: up to 1 year ]
    Time-to-Best Response by RECIST v1.1 and iRECIST

  4. Duration of Response (DOR) [ Time Frame: up to 1 year ]
    Duration of Response (DOR) by RECIST v1.1 and iRECIST

  5. Progression-Free Survival (PFS) [ Time Frame: up to 6 months ]
    6month- PFS by RECIST v1.1 and iRECIST

  6. Overall Survival (OS) [ Time Frame: up to 1 year ]
    Overall Survival (OS) by RECIST v1.1 and iRECIST

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients must be female and age ≥ 18 years (19 years for Korean sites)
  2. Patients with histologically confirmed advanced or metastatic HPV-positive (HPV-16 or HPV-18) cervical cancer, who have disease progression after treatment with all available therapies for metastatic disease that are known to confer clinical benefit, or are intolerant to treatment, or refuse standard treatment.
  3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
  4. Life Expectancy of at least 6 months
  5. Patients must agree to provide either an archival tumor tissue sample or fresh biopsy sample for baseline biomarker tissue analyses, including staining for PD-L1. If archival tissue is not available and the patient does not have biopsy-accessible tumor lesions, the patient will be excluded.

Exclusion Criteria:

  1. Patient has disease that is suitable for local therapy administered with curative intent.
  2. Patient has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
  3. Patient is expected to require any other form of antineoplastic therapy while on study; including systemic chemotherapy, radiation therapy (except for palliative purposes) biological therapy, or immunotherapy not specified in this protocol.
  4. Patient has a history of active central nervous system (CNS) metastases and/or carcinomatous meningitis.
  5. Patients have received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137) and was discontinued from that treatment due to a Grade 3 or higher immune-related Adverse Event (irAE)
  6. Patients with active autoimmune disease requiring systemic immunosuppressive treatment within the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.
  7. Patients has had an allogeneic solid organ or allogeneic bone marrow transplant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03444376

Layout table for location information
Korea, Republic of
Keimyung University Dongsan Medical Center
Daegu, Korea, Republic of, 42601
National Cancer Center
Gyeonggi-do, Korea, Republic of, 10408
Seoul National University Bundang Hospital
Gyeonggi-do, Korea, Republic of, 13620
Severance Hospital, Yonsei University Health System
Seoul, Korea, Republic of, 03722
Asan Medical Center
Seoul, Korea, Republic of, 05505
Samsung Medical Center
Seoul, Korea, Republic of, 06351
The Catholic University of Korea Seoul St. Mary's Hospital
Seoul, Korea, Republic of, 06591
Korea University Guro Hospital
Seoul, Korea, Republic of, 152-703
Sponsors and Collaborators
Genexine, Inc.
Merck Sharp & Dohme LLC
Layout table for investigator information
Principal Investigator: Soo-Young Hur, M.D The Catholic University of Korea
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Genexine, Inc.
ClinicalTrials.gov Identifier: NCT03444376    
Other Study ID Numbers: GX-188E-005
First Posted: February 23, 2018    Key Record Dates
Last Update Posted: April 6, 2022
Last Verified: February 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Genexine, Inc.:
TDS-IM device
Additional relevant MeSH terms:
Layout table for MeSH terms
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Cervical Diseases
Uterine Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents